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A B S T R A C T
Background: Diet and smoking are the main sources of cadmium exposure in the general population.
Cadmium increases the risk of cardiovascular diseases, and experimental studies show that it induces
inﬂammation. Blood cadmium levels are associated with macrophages in human atherosclerotic plaques.
Soluble urokinase-type plasminogen activator receptor (suPAR) is an emerging biomarker for cardiovascular
events related to inﬂammation and atherosclerotic plaques. The aim was to examine whether blood cadmium
levels are associated with circulating suPAR and other markers of inﬂammation.
Methods: A population sample of 4648 Swedish middle-aged women and men was examined cross-sectionally
in 1991–1994. Plasma suPAR was assessed by ELISA, leukocytes were measured by standard methods, and
blood cadmium was analysed by inductively coupled plasma mass spectrometry. Prevalent cardiovascular
disease, ultrasound-assessed carotid plaque occurrence, and several possible confounding factors were
recorded.
Results: After full adjustment for risk factors and confounding variables, a 3-fold increase in blood cadmium
was associated with an 10.9% increase in suPAR concentration (p < 0.001). In never-smokers, a 3-fold increase
in blood cadmium was associated with a 3.7% increase in suPAR concentration (p < 0.01) after full adjustment.
Blood cadmium was not associated with C-reactive protein, white blood cell count and Lp-PLA2 but with
neutrophil/lymphocyte ratio in one of two statistical models.
Conclusions: Exposure to cadmium was associated with increased plasma suPAR in the general population,
independently of smoking and cardiovascular disease. These results imply that cadmium is a possible cause for
raised levels of this inﬂammatory marker.
1. Introduction
The general population is exposed to cadmium by consuming food
items such as rice, wheat, vegetables, and potatoes; and, for those who
smoke, by uptake of cadmium from tobacco smoke in the lungs
(Nordberg et al., 2015). Cadmium is mainly accumulated in the
kidneys, and is eliminated very slowly, with a half time of decades.
Cadmium in blood is aﬀected by recent exposure, but at stable
environmental exposure it reﬂects the body burden (Nordberg et al.,
2015; Akerstrom et al., 2013). Cadmium is a non-essential metal with
toxic eﬀects resulting in increased risks of adverse eﬀects on kidney and
bone as well as some malignant diseases and premature death
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(Åkesson et al., 2014; Larsson et al., 2015). An accumulating body of
data shows that cadmium exposure is also associated with increased
risk of atherosclerotic diseases such as myocardial infarction and
stroke (Larsson et al., 2015). The evidence is based on experimental
(Subramanyam et al., 1992; Messner et al., 2009; Knoﬂach et al., 2011;
Almenara et al., 2013), cross-sectional, and prospective studies of
clinical events (Tellez-Plaza et al., 2013; Barregard et al., 2016), and on
investigations of subclinical atherosclerosis in diﬀerent vascular beds
(Fagerberg et al., 2012, 2015; Bergström et al., 2015).
There is an uptake of cadmium in many organs including liver,
arterial vessel wall, and atherosclerotic plaques (Bergström et al., 2015;
Vuori et al., 1979). Many toxic mechanisms have been demonstrated,
with the pro-inﬂammatory eﬀects particularly in focus (Olszowski
et al., 2012). The majority of these studies, which have been performed
in vitro and in vivo in diﬀerent cell lines, in animal models, and in
humans, suggest that cadmium causes up-regulation of the mediators
and markers of inﬂammation (Olszowski et al., 2012).
Inﬂammation is an important component of the atherosclerotic
disease process (Packard and Libby, 2008). Many circulating inﬂam-
matory biomarkers have been linked to cardiovascular diseases,
although the underlying mechanisms are poorly known (Lubrano
et al., 2015). Serum C-reactive protein (CRP) and white blood cell
count (WBC) are well-known such markers (Emerging Risk Factors
Collaboration, Kaptoge et al., 2010; Madjid et al., 2004). The ratio of
the neutrophil to lymphocyte count may carry speciﬁc and strong
information on future coronary risk (Fowler et al., 2013). Lipoprotein-
associated phospholipase A2 (Lp-PLA2), which is involved in the
metabolism of oxidized low-density lipoprotein (LDL), is an established
predictor of future cardiovascular disease (Maiolino et al., 2015).
The urokinase-type plasminogen activator receptor (uPAR) is a
membrane-bound protein that is highly expressed in macrophages and
in symptomatic atherosclerotic plaques, and is locally enriched within
symptomatic plaques (Svensson et al., 2004, 2008; Steins et al., 2004).
Both uPAR and cadmium seem to accumulate in close connection to
macrophages in symptomatic carotid plaques (Svensson et al., 2008;
Fagerberg et al., 2016). uPAR is associated with ﬁbrinolysis, cell
migration, and matrix degeneration (Hodges et al., 2015). It is also
released from the cell surface into blood in a soluble form (suPAR) and
may reﬂect a pathophysiological pathway more closely linked with
subclinical organ damage than CRP, which to a large extent mirrors
obesity and dysmetabolism (Hodges et al., 2015). suPAR levels reﬂect
low-grade inﬂammation, and are associated with lifestyle factors such
as smoking, alcohol intake, and sedentary lifestyle; in addition, women
have higher levels than men (Hodges et al., 2015). suPAR is a novel
circulating biomarker, and may outperform traditional markers of
inﬂammation such as CRP in prognosticating diﬀerent cardiovascular
diseases (Hodges et al., 2015; Persson et al., 2012, 2014). No previous
studies have examined whether cadmium exposure is associated with
suPAR.
Two population-based studies from National Health and Nutrition
Examination Survey (NHANES) have shown associations between
urinary cadmium levels and high-sensitivity CRP levels, and these
associations also hold after adjustment for smoking (Lin et al., 2009;
Colacino et al., 2014) and in never-smokers (Colacino et al., 2014).
However, one of these studies found a negative association between
cadmium and WBC (Colacino et al., 2014). In contrast, a previous in
vivo study on rats demonstrated a potential positive association
between acute cadmium exposure and increased WBC (Morgan et al.,
1984).
It is known that food items such as ﬁbre and vegetables have the
dual eﬀects of both being important contributors to a high cadmium
intake and conferring an anti-inﬂammatory eﬀect (Nordberg et al.,
2015). This anti-inﬂammatory eﬀect was suggested in the present
cohort, in which a high intake of ﬁbre, fruits, and vegetables was
signiﬁcantly correlated with lower CRP levels (Dias et al., 2015). These
data suggest that diet composition may reduce the pro-inﬂammatory
eﬀect of cadmium exposure; and, indeed, in NHANES a diet rich in
anti-inﬂammatory nutrients was associated with a reduction in CRP
(Colacino et al., 2014).
We hypothesized that cadmium exposure is associated with an
increase in circulating suPAR concentrations independently of known
covariates related to sex, lifestyle, and anti-inﬂammatory nutrients. We
also wanted to explore the associations between cadmium exposure,
CRP, total WBC, the neutrophil to lymphocyte ratio, and Lp-PLA2.
2. Materials and methods
As previously described, all men and women in the city of Malmö,
Sweden, born between 1923 and 1950, were invited to participate in
the Malmö Diet and Cancer Study (MDCS), which aimed to examine
the association between dietary factors and cancer (Berglund et al.,
1993). Between 1991 and 1994, a random selection of half of those
included in the MDCS and born between 1926 and 1945 were invited to
a cardiovascular sub-study including ultrasound measurement of
carotid atherosclerosis (Fagerberg et al., 2015; Hedblad et al., 2000).
Of the 6103 participants in the cardiovascular sub-cohort fasting blood
samples were provided by 5540. The present study included partici-
pants with data available on cadmium in blood and circulating
biomarkers of inﬂammation (n=4648). Reasons for exclusions were
missing data on cadmium in blood (n=592), suPAR (n=204) CRP
(n=134) and Lp-PLA2 activity (n=136). Mean age was identical
between the total sub-cohort and the participants in the present study
(57.5 years in both cases). Women constituted 60.0% and 59.2%,
respectively, of these cohorts.
2.1. Cardiovascular risk factors
As previously reported the participants visited the study centre on
three occasions (Hedblad et al., 2000; Wirfält et al., 2001; Rosvall
et al., 2005). At the ﬁrst visit the study questionnaires were distributed
and the anthropometric measurements were performed. Non-fasting
blood samples were taken, haematocrit, lymphocytes and neutrophils
were analysed. Erythocytes were separated and stored in biobank. At
the second visit trained interviewers conducted a diet history interview
and checked the correctness of questionnaires. At the third visit fasting
blood samples were drawn and stored in a biobank (Supplement).
Dietary habits were assessed by using a modiﬁed diet-history
method, combining a 168-item quantitative diet history questionnaire,
a 7 d menu book and a 1 h dietary interview (Wirfält et al., 2001; Dias
et al., 2015). Fibre and vegetable intake data were adjusted for total
energy consumption (g/MJ). The diet data were in the regression
analyses adjusted for season during year the examination was per-
formed (see Supplement).
Participants were categorized into never-smokers, ex-smokers, and
current smokers. Information on pack-years was available in 3707
subjects. (Fagerberg et al., 2015). Daily alcohol intake was calculated.
Deﬁnitions of cardiovascular risk factors in the present study has
been presented previously (Manjer et al., al., 2002; Rosvall et al.,
2000). Educational level was deﬁned as the number of years of
completed education. Low education included those who had < 9 years
of education. A low leisure-time physical activity was deﬁned as
individuals belonging to the bottom quartile of the obtained physical
activity score, modiﬁed from the Minnesota Leisure Time Activity
Questionnaire. Alcohol intake was classiﬁed as high in women con-
suming > 30 g/day and in men with > 40 g/day. The self-administered
questionnaire was used to acquire information on use of lipid-lowering,
antihypertensive and antidiabetic drugs at baseline. Subjects were
classiﬁed as having diabetes mellitus if they reported the diagnosis in
the questionnaire, if they had a fasting venous whole blood glucose
≥6.1 mmol/L, or if they were taking medication for diabetes mellitus.
Biochemical measurements of blood glucose, total cholesterol, high-
density lipoprotein (HDL) cholesterol, and triglycerides, as well as the
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calculation of LDL cholesterol, were performed according to usual
practice (Hedblad et al., 2000).
2.2. Cardiovascular disease, subclinical atherosclerosis
Previous myocardial infarction and stroke were assessed by ques-
tionnaire and register data (Rosvall et al., 2005). In connection with the
ﬁrst visit in the study, subjects underwent B-mode ultrasonography
(Acuson128 CT system, Siemens, Mountain View, Ca, USA) of the right
carotid artery, according to a standardized protocol, performed by
trained, certiﬁed sonographers (Rosvall et al., 2000). Atherosclerotic
plaques were deﬁned as a focal thickening of the intima-media
complex > 1.2 mm and with an area ≥10 mm2. We have previously
reported that blood cadmium levels are associated with the prevalence
of carotid plaques after adjustment for cardiovascular risk factors
(Fagerberg et al., 2015).
2.3. Inﬂammatory biomarkers
WBC, neutrophil, and lymphocyte counts were measured at base-
line. The biobank was used to measure CRP (2002), Lp-PLA2 activity
(2005), suPAR (2011) and cadmium (2012–2013). WBC, neutrophil,
and lymphocyte counts (cells/L) were measured according to standard
procedures at the Department of Clinical Chemistry, Skåne University
Hospital, Malmö. CRP was analysed using a high-sensitivity assay, the
Tina-quant® CRP latex assay (Roche Diagnostics, Basel, Switzerland),
on an ADVIA® 1650 Chemistry System (Bayer Healthcare, NY; USA).
Plasma levels of suPAR were measured in plasma drawn at baseline
and stored at −80 °C, using the commercial ELISA suPARnostic® kit
(ViroGates, Copenhagen, Denmark). The inter-assay and intra-assay
coeﬃcients of variation were 9.2% and 2.1%, respectively. Lp-PLA2
activity (nmol/min/mL) was determined via a radiometric high-
throughput activity assay.
2.4. Blood cadmium and lead concentrations
Cadmium is located in erythrocytes in blood, with a marginal
concentration in plasma (Nordberg et al., 2015). Cadmium was
analysed in erythrocytes which had been stored at −80 °C since
baseline. Pipettes and vials used when obtaining erythrocytes from
the biobank for the present study were carefully checked and found not
to contribute to any contamination. The cadmium levels in the
population were similar to those found in other studies of Swedish
populations of the same age (Akesson et al., 2005). Whole blood
cadmium concentration was calculated from erythrocyte cadmium and
haematocrit. The analysis was performed using inductively coupled
plasma mass spectrometry (Agilent 7700x ICP-MS; Agilent
Technologies, Sankta Clara, Ca, USA) operating in the helium collision
cell mode, as described previously in detail (Fagerberg et al., 2015).
The imprecision (coeﬃcient of variation) was 9.6%, as calculated for 50
duplicate samples. The limit of detection was 0.02 µg/L; no samples
had levels below this. Analysis of external quality control samples and
an interlaboratory comparison showed satisfactory results (Fagerberg
et al., 2015).
Lead concentration in erythrocytes were also analysed in parallel
with the cadmium analysis and haematocrit was used to calculate blood
lead concentrations as reported previously (Gambelunghe et al., 2016).
2.5. Statistical analyses
Characteristics of the participants are shown by sex-speciﬁc quar-
tiles of cadmium. Results are presented as means (standard deviation
[SD]) for continuous variables and as percentages for categorical
variables. Blood cadmium, serum triglyceride and plasma glucose
concentrations as well as all circulating inﬂammatory markers were
skewed variables and are presented as median (25th, 75th percentiles)
in Tables 1, 2. Diﬀerences between groups were analysed with t-test,
analysis of variance (ANOVA, trend) after log transformation of skewed
variables (see above). Diﬀerences in proportions were analysed with a
chi-squared test. Pearson's correlation coeﬃcient was calculated.
The variables which were identiﬁed as potential confounders of
associations between blood cadmium and inﬂammatory markers were
sex, age, low education level, low level of physical activity, dietary
intake of ﬁbre and vegetables, smoking history, high alcohol intake,
previous cardiovascular disease, body mass index (BMI), HDL choles-
terol, triglycerides, and occurrence of carotid plaques as assessed by
ultrasound (Tables 1–3) (Nordberg et al., 2015; Hodges et al., 2015;
Persson et al., 2014; Fagerberg et al., 2015). Interaction terms were
introduced for blood cadmium and sex, as well as age. In sensitivity
analyses the associations with blood lead levels, pack-years and time
since smoking cessation were examined. The associations between
smoking history as well as time since smoking cessation in ex-smokers
and circulating markers of inﬂammation were also examined.
Linear regression analysis adjusting for the covariates listed above
was used to analyse the associations between blood cadmium and
circulating inﬂammatory biomarkers. Blood cadmium, triglycerides,
and the inﬂammatory biomarkers were skewed, and hence were natural
log (ln) transformed for the analyses. Firstly, estimates with 95%
conﬁdence intervals are presented as percentage change in inﬂamma-
tory biomarkers for a threefold increase of blood cadmium. Secondly,
an additional analysis was performed by analyzing changes in inﬂam-
matory markers by quartiles of blood cadmium after full adjustment for
potential confounders. Dummy variables for cadmium quartiles 2, 3
and 4 were created and changes of biomarkers for each of these
quartiles in relation to those in quartile 1 were calculated as well as
95% conﬁdence intervals. These two analyses were conducted both in
the entire study group and in the never smoking group. Signiﬁcance
tests were two-sided, and p < 0.05 was considered statistically signiﬁ-
cant. All analyses were performed using version 20 of the SPSS
software package (IBM Corp.).
3. Results
Characteristics of the participants are shown in Table 1. On
average, blood cadmium concentrations were slightly higher in women
than in men (p < 0.001). Increasing quartiles of blood cadmium were
associated with low BMI, low educational level, low degree of physical
activity, and low intake of ﬁbre and vegetables. High blood cadmium
levels were associated with current and previous smoking, higher
alcohol intake, blood lead and serum triglycerides as well as higher
prevalences of carotid plaques and previous cardiovascular disease.
Elevated cadmium concentrations were associated with low serum
HDL cholesterol. Circulating concentrations of suPAR, CRP, WBC,
neutrophil/lymphocyte ratio, and Lp-PLA2 activity were positively
associated with blood cadmium (Table 2). Blood lead showed statisti-
cally signiﬁcant correlation with blood cadmium (r=0.24, p < 0.001),
WBC (r=0.066, p < 0.001) and Lp-PLA2 Activity (r=0.056, p < 0.001)
but not with suPAR, CRP, or neuthrophil/lymphocyte ratio
(Supplement).
All inﬂammatory biomarkers showed signiﬁcant positive correla-
tions with BMI and glucose and negative correlations with HDL
cholesterol, with the exception of neutrophil/lymphocyte ratio
(Table 3). LDL cholesterol was strongly positively correlated with Lp-
PLA2 activity, and negatively correlated with neutrophil/lymphocyte
ratio. With the exception of neutrophil/lymphocyte ratio, all biomar-
kers were positively correlated with triglycerides. All inﬂammatory
biomarkers showed negative correlations with dietary intake of ﬁbre
and vegetables, respectively.
As shown in Table 4, the levels of all inﬂammatory markers were
increased in current smokers compared with those in never-smokers.
The CRP and WBC levels in previous smokers were signiﬁcantly higher
than those in never-smokers.
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The mean time since smoking cessation in previous smokers was 18
years, ranging from 1–53 years. As presented in Supplemental Table S2
CRP and WBC gradually decreased over time since smoking cessation
(p < 0.001 for both), whereas no corresponding change were observed
in the remaining inﬂammatory markers.
Multivariable analyses were performed, with adjustment for sex
and age in the ﬁrst step and for covariates associated with both blood
cadmium and inﬂammatory biomarkers in the second step. The results
showed that elevation of blood cadmium was associated with increases
in all inﬂammatory biomarkers (Table 5). In subsequent similar
analyses that only included never-smokers, similar ﬁndings were only
obtained with suPAR and neutrophil/lymphocyte ratio (Table 6).
Hence, in all participants, irrespective of smoking history, a 3-fold
increase in blood cadmium was associated with a 10.9% (p < 0.001)
increase in suPAR concentration after full adjustment and a 5.0% (p <
0.001) increase in neutrophil/lymphocyte ratio. In never-smokers, a 3-
fold increase in blood cadmium was associated with a 3.7% (p < 0.01)
increase in suPAR concentration after full adjustment and a 4.6% (p <
0.05) increase in neutrophil/lymphocyte ratio.
In a sensitivity analysis with adjustment for blood lead concentra-
tions and also pack-years in a subgroup of participants with such data
available there was no principal change of the results (Supplemental
Table S3). Similar results were also obtained with further adjustment
for time since smoking cessation (Table S3). Addition of ln-trans-
formed CRP to the linear regressions did not change the results (data
not shown). A multivariable regression analysis including potential
confounders did not show any statistically signiﬁcant interactions
between blood cadmium and sex or between blood cadmium and age,
neither in the total study group, nor in the never-smoking
(Supplemental Table S4).
In the additional, alternative statistical model with analyses of
changes in inﬂammatory markers by quartiles of blood cadmium the
results were similar to those obtained as by the ﬁrst model
(Supplemental Tables S5, S6). The exception was the neutrophil/
lymphocyte ratio that did not show statistically signiﬁcant change
between blood cadmium quartiles in never smokers.
4. Discussion
In the present study, we found that blood cadmium concentrations
were associated with circulating suPAR levels after adjustment for all
potential confounders. These relationships were also found in the
subgroup of never-smokers.
A seemingly contradictory ﬁnding is the negative association
between blood cadmium and the intake of ﬁbre and vegetables, which
are the main sources of high cadmium dietary consumption (Nordberg
et al., 2015). This is explained by the confounding eﬀect of smoking as
the major source of high exposure to cadmium in general populations.
In the group of never smokers, there was a positive association between
cadmium and intake of dietary ﬁbres and vegetables (see Supplemental
Table S1).
Smoking is a major confounder; it is closely associated both with
cadmium levels and with the inﬂammatory biomarkers, which were
increased in current smokers compared with never-smokers. This
ﬁnding might be explained by a pro-inﬂammatory eﬀect of tobacco
smoke (Csordas et al., 2013). We tried to clarify this issue with a cross-
sectional analysis of the association between time since smoking
cessation and levels of inﬂammatory markers. The results clearly
indicated that CRP concentration and WBC count decreased very
slowly over time, and after several decades reached similar levels to
those in never-smokers. These data support the notion that tobacco
smoke has proinﬂammatory eﬀects on these biomarkers which wane
Table 1
Characteristics of the study cohort at baseline by sex-specific quartiles of blood cadmium.
Variable ALL n=4648 Sex-specific quartiles of blood cadmium (Q1-Q4) p-value for trend
1 (n=1161 2 (n=1162) 3 (n=1163) 4 (n=1162)
Blood cadmium, μg/L –
(median, percentile 25,75)
All 0.26 (0.17, 0.50) 0.13 (0.11, 0.15) 0.21 (0.19, 0.23) 0.33 (0.29, 0.40) 0.99 (0.68,1.47)
Women 0.27 (0.18, 0.49) 0.14 (0.12, 0.16) 0.22 (0.20, 0.24) 0.34 (0.30, 0.40) 0.97 (0.68, 1.45)
Men (n, Q1–Q4=473/473/474/473) 0.24 (0.15, 0.50) 0.12 (0.10, 0.14) 0.19 (0.17, 0.21) 0.31 (0.27, 0.39) 0.99 (0.70, 1.49)
Women, n (%) 2755 (59.2) 688 (59.2) 689 (59.2) 689 (59.2) 689 (59.2) 0.99b
Age, (mean ± SD), yrsa 57.5 ± 5.9 57.0 ± 5.9 57.7 ± 6.0 58.3 ± 5.8 56.8 ± 5.9 0.75a
BMI, (mean ± SD), kg/m2 25.6 ± 3.9 25.8 ± 4.0 25.9 ± 3.9 25.9 ± 3.8 25.1 ± 4.0 < 0.001
Waist, (mean ± SD), cma 83.6 ± 12.8 83.5 ± 12.7 83.8 ± 13.2 83.9 ± 12.5 83.0 ± 12.9 0.39a
Low educational level ( < 9 years of schooling), n (%) 2 091 (46.2) 462 (40.3) 505 (44.4) 531 (47.2) 593 (52.9) < 0.001b
Low physical activity, n (%) 1040 (23.1) 236 (20.6) 251 (22.2) 255 (22.8) 298 (26.8) 0.005b
Intake of ﬁbre, (mean ± SD), g/MJ 2.4 ± 0.7 2.5 ± 0.7 2.4 ± 0.8 2.4 ± 0.7 2.1 ± 0.7 < 0.001a
Intake of vegetables, (mean ± SD), g/MJ 21.1 ± 12.7 22.2 ± 13.0 21.7 ± 13.2 21.0 ± 11.9 19.6 ± 12.7 < 0.001a
High alcohol intake, n (%) 165 (3.6) 35 (3.1) 37 (3.3) 35 (3.1) 58(5.2) 0.012b
Smoking status, n (%) 4551 < 0.001b
Never-smoker 1825 (40.1) 740 (63.3) 587(51.6) 431 (38.2) 67 (5.9)
Ex-smoker 1732 (38.1) 395 (34.6) 528 (46.4) 580 (51.5) 226 (19.9)
Current smoker 994 (21.8) 13 (1.1) 22 (1.9) 116 (10.3) 843 (74.2)
Previous cardiovascular disease, n (%) 109 (2.3) 8 (0.7) 24 (2.1) 40 (3.5) 37 (3.2) < 0.001b
Carotid plaque, n (%) 1585 (35.4) 341 (30.4) 363 (32.4) 392 (35.1) 489 (43.8) p < 0.001b
Lipid lowering treatment, n (%) 107 (2.3) 23 (2.0) 21 (1.8) 38 (3.3) 25 (2.2) 0.33b
Blood pressure lowering treatment, n (%) 740 (15.9) 164 (14.1) 200 (17.2) 210 (18.1) 166 (14.3) 0.78b
Diabetes mellitus, n (%) 416 (9) 116 (10) 103 (9) 101 (9) 96 (8) 0.15b
Systolic blood pressure, (mean ± SD), mmHg 141 ± 19 140 ± 18 141 ± 19 142 ± 20 140 ± 20 0.68
Diastolic blood pressure, (mean ± SD), mmHg 87 ± 9 86 ± 9 87 ± 9 87 ± 9 87 ± 9 0.44a
LDL cholesterol, (mean ± SD), mmol/L 4.18 ± 0.99 4.17 ± 1.01 4.18 ± 0.96 4.14 ± 0.94 4.23 ± 1.04 0.28a
HDL cholesterol, (mean ± SD), mmol/L 1.39 ± 0.37 1.39 ± 0.37 1.41 ± 0.38 1.40 ± 0.37 1.35 ± 0.37 0.01a
Serum triglycerides, mmol/L (median, percentile 25,75) 1.16(0.87, 1.60) 1.13(0.85, 1.61) 1.11(0.85, 1.57) 1.15(0.86, 1.56) 1.24(0.93, 1.70) 0.001a
Plasma glucose, mmol/La (median, percentile 25,75) 4.90 (4.60, 5.30) 4.90 (4.60, 5.30) 4.90 (4.60, 5.30) 4.90 (4.60, 5.30) 4.90 (4.60, 5.30) 0.45a
Blood lead, µg/L (median, percentile 25,75) 25.5 (19.1, 34.2) 22.2 (16.8, 29.4) 24.6 (18.8, 33.1) 26.2 (19.5, 34.7) 29.4 (22.4, 39.9) < 0.001a
Data are presented as mean ( ± SD), unless else is presented. HDL, high density cholesterol; LDL, low density cholesterol.
a ANOVA.
b Chi2 test for trend.
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over time after smoking cessation. In a previous study, CRP gradually
decreased over 40 years following smoking cessation, but the conclu-
sion was that the lifetime exposure to smoking was even more
important (Tracy et al., 1997).
An alternative explanation might be that tobacco smoking is a
strong pro-atherosclerotic factor, and that atherosclerotic disease per
se is associated with inﬂammation (Colacino et al., 2014). We
performed multivariable linear regression analyses adjusted for poten-
tial confounding factors for cadmium and inﬂammation, including
smoking history with participants classiﬁed as never-smokers, ex-
smokers, and current smokers. In these analyses, all inﬂammatory
markers remained signiﬁcantly associated with blood cadmium.
However, residual confounding by smoking could not be excluded,
and so we performed subgroup analyses in never-smokers, demon-
strating that only suPAR and neutrophil/lymphocyte ratios were
independently associated with blood cadmium. Neither CRP, WBC,
nor Lp-PLA2 showed any association with blood cadmium in never-
smokers. As mentioned above, a previous NHANES study found a
positive association between urinary cadmium and CRP in never-
smokers, as well as a negative association with WBC (Colacino et al.,
2014).
Our ﬁnding that suPAR was independently associated with blood
cadmium supports our hypothesis and raises the question whether
elevated suPAR may be explained by underlying atherosclerotic
Table 2
Inflammatory biomarkers by sex-specific quartiles of blood cadmium.
Variable ALL
n=4648
Sex-specific quartiles of blood cadmium (Q1–Q4) p-
value
for
trend
1(n=1161 2
(n=1162)
3
(n=1163)
4
(n=1162)
suPAR, ng/
mL
(median,
percen-
tile
25,75)
2.81
(2.42,
3.38)
2.60
(2.29,
3.04)
2.68
(2.33,
3.13)
2.81
(2.42,
3.35)
3.36 (2.74,
4.12)
<
0.001a
CRP, mg/L
(median,
percen-
tile
25,75)
1.40
(0.70,
2.80)
1.20
(0.60,
2.40)
1.20
(0.60,
2.40)
1.30
(0.70,
2.70)
1.70 (0.80,
3.80)
<
0.001a
WBC, 109/L
,
(median,
percen-
tile
25,75)
5.8(5.0,
6.9)
5.4(4.8,
6.4)
5.5(4.8,
6.5)
5.6(4.9,
6.7)
6.8(5.7,
8.1)
<
0.001a
Neutrophil
count/
lympho-
cyte
count,
ratio
(median,
percen-
tile
25,75)
2.00
(1.53,
2.53)
1.88
(1.46,
2.43)
1.93
(1.51,
2.53)
1.95
(1.56,
2.47)
2.13(1.64,
2.67)
<
0.001a
Lp-PLA2
activity,
(nmol/
min/
mL)
(median,
percen-
tile
25,75)
44.22
(36.25,
53.02)
43.42
(35.84,
52.37)
43.29
(35.18,
52.54)
43.80
(36.07,
52.60)
46.00
(38.08,
54.41)
<
0.001a
Data are presented as mean ( ± SD) unless else is presented. suPAR, soluble urokinase
plasminogen activator receptor; CRP, high sensitive C-reactive protein; WBC, white
blood cell count; Lp-PLA2, lipoprotein-associated phospholipase A2. All p-values are
two-sided.
a ANOVA.
Table 3
Correlations between cardiovascular risk factors, dietary intake, and inflammatory biomarkers.
Variable BMI Plasma glucose LDL cholesterol HDL cholesterol Triglycerides Dietary intake
Fibre Vegetables
suPAR 0.092*** 0.119*** 0.036* −0.132*** 0.119*** −0.066*** −0.062***
CRP 0.314*** 0.161*** 0.028 −0.199 0.180*** −0.072*** −0.034*
WBC 0.109*** 0.071*** 0.026 −0.134*** 0.172*** −0.130*** −0.073***
Neutrophil/ lymphocyte count −0.099*** 0.024 −0.059*** −0.015 −0.026 −0.084*** −0.081***
Lp-PLA2 Activity 0.075*** 0.075*** 0.470*** −0.308*** 0.307*** −0.074*** −0.114***
Abbreviations as in Table 1. Inﬂammatory markers, plasma glucose and triglycerides were ln-transformed and Pearson’s correlation coeﬃcient was calculated.
* p < 0.05.
*** p < 0.001.
Table 4
Inflammatory biomarkers by smoking history (medians, 25 and 75 percentiles).
Variable Smoking history
Never
(n=1817)
Previous
(n=1533)
Current (1182)
suPAR, ng/mL 2.71 (2.35,
3.15)
2.69 (2.35, 3.18) 3.30 (2.65,
4.06)***
CRP, mg/L 1.20 (0.60,
2.40)
1.30 (0.70,
2.70)**
1.60 (0.80,
3.60)***
WBC, 109/L 5.5 (4.8, 6.5) 5.6 (4.4, 6.6)** 6.8 (5.6, 7.9)***
Neutrophil/
lymphocyte ratio
1.91 (1.50,
2.46)
1.95 (1.53, 2.53) 2.10 (1.61,
2.65)***
Lp-PLA2 Activity,
nmol/min/mL
43.10 (35.21,
51.94)
43.65 (36.11,
52.92)
45.83 (38.08,
54.31)***
Abbreviations as in Table 1.
** p < 0.01.
*** p < 0.001 in comparison with never-smokers (t-test).
Table 5
Percentage change in inflammatory biomarkers by a 3-fold increase in blood cadmium
level in all participants.
Inﬂammatory
biomarker
Adjusted for
sex, age
95% CI Fully
adjusteda
95% CI
suPAR 14.1*** 13.0, 15.1 10.9*** 9.4, 12.4
CRP 22.4*** 17.8, 27.3 18.2*** 12.2, 24.6
WBC 12.2*** 11.2, 13.2 8.5*** 7.2, 9.9
Neutrophil count/
lymphocyte count
5.6*** 4.1, 7.2 5.0*** 2.9, 7.2
Lp-PLA2 Activity 3.2*** 2.2, 4.4 2.6*** 1.1, 4.0
a Linear regression with adjustment for age, sex, BMI, low educational level (yes/no),
low physical activity (yes/no), smoking history (0- never, 1-ever, 2-current), high alcohol
intake (yes/no), intake of vegetables and ﬁbre, season for dietary examination (spring,
summer, autumn, winter), previous cardiovascular disease (yes/no), carotid plaque (yes/
no), serum triglycerides (ln-transformed), HDL cholesterol.
*** p < 0.001.
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disease. Firstly, it has been shown in the present cohort that serum
suPAR predicts cardiovascular disease and subclinical carotid athero-
sclerosis (Persson et al., 2012, 2014). In comparison with CRP, the
serum levels of suPAR are more strongly related both to carotid
plaques as assessed by ultrasound, and to coronary atherosclerosis as
measured with calcium score (Lyngbæk et al., 2013; Sørensen et al.,
2014). Secondly, both cadmium and suPAR co-vary with the accumu-
lation of macrophages in carotid plaques, and cadmium has pro-
inﬂammatory eﬀects (Bergström et al., 2015; Olszowski et al., 2012;
Svensson et al., 2004, 2008; Fagerberg et al., 2016; Edsfeldt et al.,
2012). However, the association between cadmium and suPAR re-
mained after inclusion of clinical cardiovascular disease and subclinical
carotid atherosclerosis as covariates in the analysis. Hence, there is no
clear indication that the association between cadmium exposure and
suPAR is mediated through enhanced atherosclerosis. Another unre-
solved question is that of whether cadmium may contribute to
increased vulnerability, including inﬂammation, in atherosclerotic
plaque (Bergström et al., 2015; Edsfeldt et al., 2012).
It is known that conditions with increased inﬂammatory activity
lead to an augmented atherosclerotic disease process (John et al.,
2012). suPAR is associated with low-grade inﬂammation, and is also
elevated in rheumatoid arthritis and other conditions (Slot et al., 1999;
Eugen-Olsen et al., 2010). Many experimental studies have shown that
cadmium has proinﬂammatory eﬀects (Olszowski et al., 2012).
Tentatively cadmium may contribute to a general low level of inﬂam-
mation, reﬂected by suPAR, which can have pro-atherosclerotic eﬀects.
We also observed in never smokers that the neutrophil/lymphocyte
ratio was independently associated with blood cadmium in one of the
two statistical models. As we could not replicate the observation in the
second statistical model our interpretation is that we still lack evidence
that neutrophil/lymphocyte ratio is associated with cadmium exposure.
This ratio non-speciﬁcally reﬂects the severity of diseases with an
inﬂammatory component, including cardiovascular diseases, diﬀerent
cancers, and mortality risk (Fowler et al., 2013; Balta et al., 2016).
Apart from cadmium, also exposure to other metals such as lead,
arsenic and mercury has been linked to increased cardiovascular risk
and often inﬂammation (Aoki et al., 2016; Sidhu et al., 2015; Houston,
2011). We found that blood lead concentrations correlated positively
with WBC and LpPLA2 Activity in univariate analysis. However, blood
lead did not confound the associations between blood cadmium and
inﬂammatory markers in multivariable analyses. Previously reported
NHANES data failed to show associations between blood lead concen-
trations and CRP, WBC and ﬁbrinogen (Songdej et al., 2010). A
limitation of the present study is that we had no data on arsenic or
mercury exposure.
A further limitation of the present study is that its cross-sectional
design meant we could not elicit any information on causal eﬀects. In
addition, although smoking is a key factor, we had no objective
measures of smoking history and insuﬃcient information on lifetime
burden of smoking, and had to rely on self-reported data.
5. Conclusions
In conclusion, we consider our results to provide robust evidence
within our study population that cadmium exposure is associated with
increased levels of suPAR. We found no support for a major mediating
eﬀect by underlying atherosclerotic disease, and suggest that the
underlying mechanism is most likely a pro-inﬂammatory eﬀect of
cadmium. Although the results have to be corroborated by other
studies, the size and quality of the present study justify the conclusion
that cadmium could be a cause for raised levels of these inﬂammatory
markers.
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